Maturitas最新文献

{"title":"Protective and harmful social and psychological factors associated with mood and anxiety disorders in perimenopausal women: A narrative review","authors":"Kayla McElhany ,&nbsp;Seema Aggarwal ,&nbsp;Geri Wood ,&nbsp;Jennifer Beauchamp","doi":"10.1016/j.maturitas.2024.108118","DOIUrl":"10.1016/j.maturitas.2024.108118","url":null,"abstract":"<div><div>Perimenopause is often called a window of vulnerability for the development or exacerbation of mood and anxiety disorders. Evidence points to social and psychological factors contributing to the onset of mood and anxiety disorders or the symptoms of depression and anxiety during perimenopause. Therefore, the purpose of this narrative review was to synthesize the findings of studies examining associations between social and psychological factors and the development of mood and anxiety disorders and the symptoms of depression and anxiety during perimenopause. PsychINFO, Ovid MEDLINE, and CINAHL were searched for studies (published between January 2014 and November 2023) assessing the social and psychological factors associated with perimenopausal mood and anxiety disorders and the symptoms of depression and anxiety. These factors were categorized as either protective or harmful. Study quality was assessed using STROBE guidelines. The search yielded 17 studies. Social support was identified as a social factor protective against perimenopausal depression and anxiety. Resiliency characteristics were reported to be protective psychological factors associated with fewer depressive symptoms. Mental health history, family history of major depressive disorder, trait anxiety and neuroticism, stressful life events, adverse childhood events, and chronic stress were categorized as harmful psychological factors associated with depression during perimenopause. Limited research has been conducted to understand factors associated with perimenopausal anxiety. The identification of these social and psychological factors associated with mood and anxiety disorders during perimenopause will help lead to earlier detection of women at risk and the development of multifaceted interventions.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population","authors":"John C. Stevenson ,&nbsp;Mulan Ren ,&nbsp;Elke Kahler ,&nbsp;Marcelo Graziano Custodio ,&nbsp;Rossella Elena Nappi ,&nbsp;Tetiana Tatarchuk ,&nbsp;Tommaso Simoncini ,&nbsp;Viktoriya Karpova ,&nbsp;Qi Yu","doi":"10.1016/j.maturitas.2024.108117","DOIUrl":"10.1016/j.maturitas.2024.108117","url":null,"abstract":"<div><h3>Objectives</h3><div>Evidence suggests ethnicity-specific differences in postmenopausal symptoms, highlighting the need for therapies that are efficacious across different ethnicities. We evaluated the efficacy of an ultra-low dose combination of 0.5 mg estradiol and 0.25 mg dydrogesterone (E 0.5 mg/D 2.5 mg) in alleviating vasomotor symptoms across a multi-ethnic population.</div></div><div><h3>Study design</h3><div>Data from two controlled trials were pooled to form a dataset of 583 postmenopausal women from across Europe and China. Participants were randomized to receive treatment with E 0.5 mg/D 2.5 mg or placebo for 12 weeks.</div></div><div><h3>Main outcome measures</h3><div>The main efficacy variable was absolute change in the number of hot flushes from baseline to end of treatment. Health-related quality of life and safety were also assessed.</div></div><div><h3>Results</h3><div>Change in the number of hot flushes per day was greater with E 0.5 mg/D 2.5 mg <em>versus</em> placebo (mean difference − 1.5, 95 % confidence interval − 2.1, −1.0; <em>p</em> &lt; 0.001). Participants treated with E 0.5 mg/D 2.5 mg reported improvement in health-related quality of life (including psychological symptoms, vaginal dryness), and high amenorrhea rates. Combined E 0.5 mg/D 2.5 mg was well tolerated: there were no differences between groups in the percentage of participants with at least one serious adverse event or treatment-emergent serious adverse events. Analysis of change in body weight indicated no differences between groups.</div></div><div><h3>Conclusions</h3><div>This pooled analysis demonstrates the consistent efficacy of E 0.5 mg/D 2.5 mg in the treatment of menopause-related symptoms across a multi-ethnic population of postmenopausal women.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224002123/pdfft?md5=bb23181ffbbca67c7fb3a3dc900e4a8a&pid=1-s2.0-S0378512224002123-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in the predictors of skeletal muscle microvascular reactivity in older individuals","authors":"Thiago Silveira Alvares ,&nbsp;Felipe Mattioni Maturana ,&nbsp;Rogerio Nogueira Soares","doi":"10.1016/j.maturitas.2024.108115","DOIUrl":"10.1016/j.maturitas.2024.108115","url":null,"abstract":"<div><p>Aging is associated with an increased risk of cardiovascular disease and vascular dysfunction. Reduced nitric oxide bioavailability is considered one of the key mechanisms underlying vascular dysfunction in large arteries of older adults. However, the relationship between cardiovascular disease risk factors, nitric oxide bioavailability, and skeletal muscle microvascular reactivity, an early hallmark in cardiovascular disease progression, is unclear in older individuals. Also uncertain is whether this relationship is influenced by sex. Therefore, this study assessed the association between cardiovascular disease risk factors, circulating markers of nitric oxide availability (plasma nitrate and nitrite), and skeletal muscle microvascular reactivity in older individuals. First, we confirmed in a cohort of young and older individuals that aging is associated with skeletal muscle microvascular dysfunction. Next, we observed that skeletal muscle microvascular reactivity (<em>P</em> = 0.653; η² = 0.016) and circulating nitric oxide metabolites (Nitrate: <em>P</em> = 0.641, η² = 0.011; Nitrite: <em>P</em> = 0.560, η² = 0.017; NOx: <em>P</em> = 0.639, η² = 0.011) did not differ between older males and females. Finally, using multivariate regression models, we found that: (i) the number of cardiovascular risk factors was negatively associated with skeletal muscle microvascular reactivity in older males and females (B = −0.132, <em>P</em> = 0.044); (ii) the relationship between plasma nitrite and skeletal muscle microvascular reactivity was influenced by sex (F = 6.837, <em>P</em> = 0.016); and (iii) skeletal muscle microvascular reactivity in older females displayed a strong positive association with plasma nitrite (R² = 0.720, <em>P</em> &lt; 0.001). While the impact of cardiovascular disease risk factors on skeletal muscle microvascular reactivity was not influenced by sex, sex-related discrepancies were found in the relationship between nitric oxide bioavailability and skeletal muscle microvascular reactivity in older individuals.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Better understanding fall risk: AI-based computer vision for contextual gait assessment","authors":"Jason Moore ,&nbsp;Peter McMeekin ,&nbsp;Samuel Stuart ,&nbsp;Rosie Morris ,&nbsp;Yunus Celik ,&nbsp;Richard Walker ,&nbsp;Victoria Hetherington ,&nbsp;Alan Godfrey","doi":"10.1016/j.maturitas.2024.108116","DOIUrl":"10.1016/j.maturitas.2024.108116","url":null,"abstract":"<div><p>Contemporary research to better understand free-living fall risk assessment in Parkinson's disease (PD) often relies on the use of wearable inertial-based measurement units (IMUs) to quantify useful temporal and spatial gait characteristics (e.g., step time, step length). Although use of IMUs is useful to understand some intrinsic PD fall-risk factors, their use alone is limited as they do not provide information on extrinsic factors (e.g., obstacles). Here, we update on the use of ergonomic wearable video-based eye-tracking glasses coupled with AI-based computer vision methodologies to provide information efficiently and ethically in free-living home-based environments to better understand IMU-based data in a small group of people with PD. The use of video and AI within PD research can be seen as an evolutionary step to improve methods to understand fall risk more comprehensively.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224002111/pdfft?md5=91997a03b833ea6d9eb7459bd0cdee2b&pid=1-s2.0-S0378512224002111-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142232620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and impact of vasomotor symptoms associated with menopause among women in Brazil: Subgroup analysis from an international cross-sectional survey","authors":"Rogério Bonassi Machado ,&nbsp;Roberto Soler ,&nbsp;Marcos Freire ,&nbsp;Maria Celeste Osorio Wender ,&nbsp;Luciano Melo Pompei","doi":"10.1016/j.maturitas.2024.108114","DOIUrl":"10.1016/j.maturitas.2024.108114","url":null,"abstract":"<div><h3>Objective</h3><div>This study assessed the prevalence and impact of moderate and/or severe vasomotor symptoms and related treatment patterns in midlife women in Brazil.</div></div><div><h3>Study design</h3><div>Brazilian women aged 40 to 65 years completed an online survey. The prevalence of moderate to severe vasomotor symptoms was assessed in postmenopausal women who completed a series of questionnaires to elicit responses regarding their treatment patterns and attitudes to treatments.</div></div><div><h3>Main outcome measures</h3><div>Perimenopausal and postmenopausal women with moderate to severe vasomotor symptoms completed three standardized questionnaires (Menopause-Specific Quality of Life questionnaire, Work Productivity and Activity Impairment questionnaire, and the Patient-Reported Outcomes Measurement Information System Sleep Disturbances Short Form 8b) and answered open-ended questions.</div></div><div><h3>Results</h3><div>Of 1244 postmenopausal women who accessed the survey, 36.2 % had experienced moderate to severe vasomotor symptoms in the previous month. Moderate to severe vasomotor symptoms among 501 perimenopausal and postmenopausal women negatively affected overall quality of life (mean total score on the Menopause-Specific Quality of Life questionnaire was 3.6/8). On the Work Productivity and Activity Impairment questionnaire, women's scores for impairments in overall work and daily activities due to vasomotor symptoms were 50.3 % and 60.0 %, respectively. Overall mean (standard deviation) score on the Patient-Reported Outcomes Measurement Information System Sleep Disturbances Short Form 8b was 25.5 (5.8) on a scale of 8 to 40. Most women sought medical advice (65.5 %), but over half were not receiving treatment. Those who received treatment reported moderately favorable attitudes to hormone and nonhormone prescription medicines, but safety concerns remained.</div></div><div><h3>Conclusion</h3><div>Brazilian women experienced a relatively high prevalence and burden of moderate to severe vasomotor symptoms.</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224002093/pdfft?md5=32337338e45360cab7520722b2a513ae&pid=1-s2.0-S0378512224002093-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the efficacy of a personalized information-provision and exercise-coaching app on the quality of life of menopausal women","authors":"Na Yeon Kim ,&nbsp;Da Seul Kim ,&nbsp;Doug Hyun Han ,&nbsp;Ji Sun Hong ,&nbsp;Yoojin Shim ,&nbsp;Youn Jung Yoon ,&nbsp;Hee Jun Kim ,&nbsp;Sun Mi Kim","doi":"10.1016/j.maturitas.2024.108113","DOIUrl":"10.1016/j.maturitas.2024.108113","url":null,"abstract":"<div><h3>Objectives</h3><p>Menopausal symptoms severely impact women's quality of life (QoL). Digital health interventions provide an accessible, personalized alternative for managing menopausal symptoms. In this study, we validated the Menopause Assistant Manager (MAMA®; Hudit, Seoul, S. Korea) app developed to provide personalized information, exercise coaching, and management of appointments and medications to menopausal women, and evaluated its efficacy on their QoL.</p></div><div><h3>Study design</h3><p>This nonrandomized interventional trial enrolled 48 peri- and postmenopausal women into experimental (MAMA) and control (Waitlist) groups (<em>n</em> = 24 each). Participants in the MAMA group used the app for 8 weeks, whereas the Waitlist group received no intervention. Both groups continued their usual treatments.</p></div><div><h3>Main outcome measures</h3><p>Clinical assessments at baseline and study completion included the World Health Organization Quality of Life Brief Version (WHOQOL-BREF), Menopause Rating Scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-15 (PHQ-15), Menopause Emotional Symptom Questionnaire, and Subjective Memory Complaints Questionnaire.</p></div><div><h3>Results</h3><p>Compared with the Waitlist group, the MAMA group showed postintervention improvements in WHOQOL-BREF physical health (F = 4.84, <em>P</em> = .03) and environmental (F = 5.01, <em>P</em> = .03) domains and GAD-7 (F = 5.53, <em>P</em> = .02) and PHQ-15 (F = 4.14, <em>P</em> = .048) scores. Changes in WHOQOL-BREF physical health scores negatively correlated with PHQ-15 scores (ρ = −0.53, <em>P</em> = .004).</p></div><div><h3>Conclusion</h3><p>By increasing treatment accessibility, the app improved physical and environmental QoL and reduced anxiety and somatic symptoms. App-based exercise coaching alleviated somatic symptoms, and the in-app psychological content reduced anxiety by normalizing menopausal symptoms, providing accurate information, decreasing uncertainty, and improving symptom perception.</p></div><div><h3>Trial registration</h3><p>Clinical Research Information Service KCT 0008603; <span><span>https://cris.nih.go.kr/cris/search/detailSearch.do?seq=25078&amp;status=5&amp;seq_group=25078&amp;search_page=M</span><svg><path></path></svg></span>.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prior pre-eclampsia does not diminish the vascular protective effect of menopausal hormone therapy","authors":"Minttu Venetkoski ,&nbsp;Hanna Savolainen-Peltonen ,&nbsp;Johanna M. Joensuu ,&nbsp;Mika Gissler ,&nbsp;Olavi Ylikorkala ,&nbsp;Tomi S. Mikkola","doi":"10.1016/j.maturitas.2024.108112","DOIUrl":"10.1016/j.maturitas.2024.108112","url":null,"abstract":"<div><h3>Objective</h3><p>Women with prior pre-eclampsia are at increased risk of cardiovascular disease (CVD). Menopausal hormone therapy (MHT) may affect this risk. We evaluated the impact of MHT use on cardiovascular risk between women with and without prior pre-eclampsia.</p></div><div><h3>Study design and main outcome measures</h3><p>We assessed the occurrence of any CVD, myocardial infarction (MI) and stroke in MHT users (<em>n</em> = 9700) and non-users (<em>n</em> = 19,914) with prior pre-eclampsia, and likewise in MHT users (<em>n</em> = 27,764) and non-users (<em>n</em> = 58,248) without prior pre-eclampsia over the period 1994–2019. Follow-up started at MHT initiation (mean age 50.4 in pre-eclamptic women and 50.3 in non-pre-eclamptic women) and lasted for a mean of 13.3 years.</p></div><div><h3>Results</h3><p>The use of MHT in prior pre-eclamptic women was associated with significant risk reductions for any CVD (HR 0.85, 95 % CI 0.78–0.91), MI (HR 0.66, 95 % CI 0.55–0.78) and stroke events (HR 0.71, 95 % CI 0.63–0.81) in comparison with non-users with prior pre-eclampsia. The risk reductions for cardiovascular deaths were even more pronounced (HR 0.43, 95 % CI 0.31–0.59 for any CVD death; HR 0.49, 95 % CI 0.30–0.80 for MI death; HR 0.25, 95 % CI 0.10–0.64 for stroke death). However, none of these risk reductions differed from those seen in MHT users without prior pre-eclampsia. The risk of any CVD decreased already within five years of MHT use in women with prior pre-eclampsia but not in those without prior pre-eclampsia.</p></div><div><h3>Conclusions</h3><p>The use of MHT is associated with reduced CVD risk in women with prior pre-eclampsia. This is important to clinicians considering the initiation of MHT for recently menopausal women with prior pre-eclampsia.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S037851222400207X/pdfft?md5=197aecea370a2ae98a580f8c545fcbbe&pid=1-s2.0-S037851222400207X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142151644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual health and wellbeing and the menopause: An EMAS clinical guide","authors":"Stavroula A. Paschou ,&nbsp;Kleoniki I. Athanasiadou ,&nbsp;Trish Hafford-Letchfield ,&nbsp;Sharron Hinchliff ,&nbsp;Melissa Mauskar ,&nbsp;Margaret Rees ,&nbsp;James A. Simon ,&nbsp;Eleni Armeni ,&nbsp;C. Tamer Erel ,&nbsp;Ivan Fistonic ,&nbsp;Timothy Hillard ,&nbsp;Angelica Lindén Hirschberg ,&nbsp;Blazej Meczekalski ,&nbsp;Nicolás Mendoza ,&nbsp;Alfred O. Mueck ,&nbsp;Tommaso Simoncini ,&nbsp;Petra Stute ,&nbsp;Dorenda van Dijken ,&nbsp;Irene Lambrinoudaki","doi":"10.1016/j.maturitas.2024.108055","DOIUrl":"10.1016/j.maturitas.2024.108055","url":null,"abstract":"<div><h3>Introduction</h3><p>Sexual health and wellbeing are significant aspects of quality of life. However, taking a sexual history is often avoided in medical practice, leaving a void in management and awareness. As the menopause can have a major impact on sexual health, it is imperative that healthcare providers are appropriately trained in sexual health and wellbeing and the aligned disciplines in order to achieve optimal care.</p></div><div><h3>Aim</h3><p>To provide an evidence-based clinical guide for the assessment and management of sexual problems at the menopause and beyond.</p></div><div><h3>Materials and methods</h3><p>Review of the literature and consensus of expert opinion.</p></div><div><h3>Results and conclusion</h3><p>The assessment of sexual problems includes history taking, examination and laboratory investigation (if indicated), and occasionally the use of specific validated questionnaires. Management of sexual problems requires a multidimensional approach using biopsychosocial measures. Medical management and psychosexual counselling include pharmacological and non-pharmacological interventions, and sex therapy and psychoeducation. Furthermore, perimenopausal women should be advised about the need for contraception if they wish to avoid pregnancy. Also, sexually transmitted diseases can be acquired at any age. To conclude, taking a sexual history should be incorporated into medical practice and healthcare providers should be appropriately trained to assess and manage sexual problems at the menopause and beyond.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menopause and sexual health: The elephant in the room","authors":"Kleoniki I. Athanasiadou ,&nbsp;Stavroula A. Paschou ,&nbsp;Irene Lambrinoudaki ,&nbsp;Margaret Rees","doi":"10.1016/j.maturitas.2024.108067","DOIUrl":"10.1016/j.maturitas.2024.108067","url":null,"abstract":"","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biopsychosocial factors intersecting with weekly sleep difficulties in the menopause transition","authors":"Sneha Chenji,&nbsp;Bethany Sander,&nbsp;Julia A. Grummisch,&nbsp;Jennifer L. Gordon","doi":"10.1016/j.maturitas.2024.108111","DOIUrl":"10.1016/j.maturitas.2024.108111","url":null,"abstract":"<div><h3>Objectives</h3><p>Sleep difficulties are common in the menopause transition and increase risk for a variety of physical and psychological problems. The current study investigated potential interactions between psychosocial variables and within-person changes in ovarian hormones in predicting perimenopausal sleep problems as well as the potential interactions between poor sleep and psychosocial factors in predicting worsened mood, affect, and attention.</p></div><div><h3>Study design</h3><p>The sample included 101 perimenopausal individuals. Participants completed 12 weekly assessments of self-reported sleep outcomes, depressive mood and affect, and attention function, and of estrone glucuronide (E1G) and pregnanediol glucuronide (PdG) levels (urinary metabolites of estradiol and progesterone, respectively); they also had 24-h tracking of vasomotor symptoms. Other psychosocial variables such as trauma history and stressful life events were assessed at baseline.</p></div><div><h3>Results</h3><p>A history of depression, baseline depressive symptoms, trait anxiety, and more severe and bothersome vasomotor symptoms predicted worsened sleep outcomes. Recent stressful life events, trauma history, and person-centred E1G and PdG changes did not predict sleep outcomes. However, there was an interaction whereby person-centred E1G decreases predicted lower sleep efficiency in those with higher baseline depressive symptoms. Higher baseline depression and trauma history also amplified the effect of vasomotor symptoms on sleep outcomes. In evaluating the effect of poor sleep on psychological and cognitive outcomes, stressful life events emerged as a moderating factor. Finally, trauma history and poor sleep interacted to predict worsened attention function.</p></div><div><h3>Conclusions</h3><p>The current study suggests that certain individuals may be at greater risk of perimenopausal sleep problems and the resulting negative effects on mood and cognition.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}